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Summary. Objectives: Stimulation of arginine vasopressin 2
receptor (V2R) with arginine vasopressin (AVP) results in a rise
in vonWillebrand factor (VWF) and factor VIII plasma levels.
We hypothesized that gain-of-function variations in the V2R
gene (AVPR2) would lead to higher plasma levels of VWF and
FVIII. Methods and Results: We genotyped the control
populations of two population-based studies for four AVPR2
variations: a-245c, G12E, L309L, and S331S. Rare alleles of
a-245c,G12E, andS331S,whichwere in linkage disequilibrium,
were associated with higher VWF propeptide, VWF and FVIII
levels. The functionality of the G12E variant was studied in
stably transfected MDCKII cells, expressing constructs of
either 12G-V2R or 12E-V2R. Both V2R variants were fully
glycosylated and expressed on the basolateral membrane. The
binding affinity of V2R for AVP was increased three-fold in
12E-V2R–green fluorescent protein (GFP) cells, which is in
accordance with increased levels of VWFpropeptide associated
with the 12Evariant.Thedissociation constant (KD)was 4.5 nM
[95% confidence interval (CI) 3.6–5.4] for 12E-V2R–GFP and
16.5 nM (95% CI 10.1–22.9) for 12G-V2R–GFP. AVP-in-
duced cAMP generation was enhanced in 12E-V2R–GFP cells.
Conclusions: The 12E-V2R variant has increased binding
affinity for AVP, resulting in increased signal transduction,
and is associated with increased levels of VWF propeptide,
VWF, and FVIII.
Keywords: arginine vasopressin 2 receptor, coagulation fac-
tor VIII, SNP, von Willebrand factor, von Willebrand factor
propeptide.
Introduction
The mechanisms underlying interindividual variations in von
Willebrand factor (VWF) and coagulation factor VIII plasma
levels are poorly understood. VWF is the carrier protein of
FVIII, and their levels therefore usually fluctuate together.
There are indications that VWF and FVIII levels are, in part,
determined genetically [1–3]. Besides ABO blood group and
variations in the genes encoding VWF and FVIII, genetic
variations in proteins involved in regulation of the plasma
levels of VWF and FVIII may contribute to variations in VWF
and FVIII levels.
A candidate modifier of VWF and FVIII levels is the
arginine vasopressin 2 receptor (V2R). The main function of
V2R is to maintain blood volume and blood pressure by
stimulating water retention in the kidney. Upon binding of
arginine vasopressin (AVP) to V2R in renal principal cells, a
cAMP signaling cascade is initiated, resulting in increased
expression of the water channel aquaporin-2 and its translo-
cation to the apical membrane. This results in reabsorption of
water from the preurine [4]. In vascular endothelial cells,
stimulation of V2R results in release of the contents ofWeibel–
Palade bodies (WPBs) into the circulation, causing a rise in
VWF and FVIII plasma levels [5]. 1-Desamino-8-d-arginine
vasopressin (desmopressin or DDAVP), a synthetic analog of
AVP, is frequently used to treat patients with mild von
Willebrand disease or hemophilia A [6]. Although it has been
suggested that only 10% of VWF is secreted through storage
organelles [7], other work has suggested that regulated secretion
of VWF is important for plasma VWF levels [8]. Amore recent
study has shown that even spontaneously released VWF is, for
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the large part, processed and secreted through post-Golgi
storage organelles [9]. Altered V2R functioning could thus
result in altered VWF and FVIII plasma levels.
We hypothesized that gain-of-function mutations in the X-
chromosomal gene encoding V2R, AVPR2, will lead to
increased VWF secretion, reflected in increased VWF propep-
tide levels, a measure of VWF secretion rate [10–12], resulting
in increased levels of mature VWF and FVIII. To test this
hypothesis, common single-nucleotide polymorphisms (SNPs)
inAVPR2were genotyped in two different populations. Allelic
distributions of these genotypes were used for association
studies with VWF propeptide, VWF and FVIII plasma levels.
In vitro studies were used to confirm SNP functionality.
Materials and methods
Study populations
Leiden Thrombophilia Study (LETS) The LETS consists
of 474 consecutive patients with a first objectively confirmed
episode of deep vein thrombosis and 474 healthy controls. For
this study, we focused on controls only. The mean age of the
control group was 45 years. The group consists of 272 women
(57.4%) and 202 men (42.6%). Individuals with underlying
malignancies were excluded. DNA samples are available for
471 controls. All participants were Caucasian and originated
from The Netherlands. The design of this study has previously
been described in detail [13,14]. FVIII antigen (FVIII:Ag),
VWF antigen (VWF:Ag) and VWF propeptide were measured
by enzyme-linked immunosorbent assay (ELISA) in the
plasma of the first 301 controls included in the study,
whereas FVIII activity (FVIII:C) was measured in the
plasma of all controls by a one-stage clotting assay [15,16].
Pooled normal plasma, calibrated against the World Health
Organization (WHO) standard for VWF and FVIII (91/666),
was used as a reference. Results for FVIII:Ag, FVIII:C and
VWF:Ag are expressed as international units per deciliter
(U dL)1). Results for VWF propeptide are expressed as units
per deciliter (IU dL)1), with 100 units being defined as the
amount of VWF propeptide in 1 dL of pooled normal plasma.
Study of Myocardial Infarctions Leiden (SMILE) The
SMILE consists of 560 patients, diagnosed with a first
myocardial infarction, and 646 controls. For this study, we
focused on controls only. The control group consists of men
who were referred to the Leiden Anticoagulation Clinic for
prophylactic anticoagulation therapy for a short period
following minor orthopedic interventions. Controls had not
used anticoagulants for a period of at least 6 months prior to
participating in this study. The mean age of the control group
was 57 years. All participants were Caucasian and originated
from The Netherlands. Plasma and DNA samples were
collected from all controls. Plasma FVIII:C was measured in
two dilutions by a one-stage clotting assay with FVIII-deficient
plasma and automated activated partial thromboplastin time
(Organon Teknika, Boxtel, The Netherlands) on a STA
(Diagnostic Stago; Boehringer Mannheim, Mannheim,
Germany). VWF:Ag was measured by ELISA. Both FVIII:C
and VWF:Ag levels are expressed as IU dL)1. Pooled normal
plasma, calibrated against an in-house standard that was
calibrated against theWHO standard for VWF and FVIII (91/
666), was used as a reference. Exclusion criteria for this study
were renal disease, severe (neuro)psychiatric problems, or a life
expectancy of < 1 year. The design of this study has
previously been described in detail [17].
Both the LETS and the SMILE were approved by the
appropriate ethical committees, and all participants gave
informed consent.
Genetic studies
Genotyping On the basis of information on frequencies and
prevalence of AVPR2 SNPs in Caucasians available in dbSNP
(www.ncbi.nlm.nih.gov/projects/SNP/) at the time, we initially
selected the following AVPR2 SNPs, located in coding regions
only: S7T (ACT>TCT), G12E (GGG>GAG), L35L
(CTG>CTA), V42A (GCG>GTG), G61V (GCC>GTC),
V147A (GCG>GTG), L309L (CTA>CTG), and S331S
(AGC>AGT). However, only G12E, L309L and S331S
(rs2071126, rs5201 and rs5202, respectively) were prevalent in
the LETS. Prevalent here means that the minor allele of an
SNP was present in the LETS population. When a minor allele
was not detected among the first 352 LETS samples tested,
genotyping of that particular SNP was discontinued.
LETS controls were genotyped for these three SNPs using
polymerase chain reaction (PCR) restriction fragment length
polymorphism analysis. PCRs and enzymatic digestions were
performed on a PTC-225 thermal cycler (Biozym, Hessisch
Oldendorf, Germany), and primers were purchased from
Eurogentec (Seraing, Belgium).
After resequencing ofAVPR2 as described below, the LETS
population was genotyped for a fourth AVPR2 variation,
a-245c (rs4898372), by 5¢-nuclease/Taqman assay. PCRs with
fluorescent allele-specific oligonucleotide probes (Applied Bio-
systems, Foster City, CA, USA) were also performed on the
PTC-225 thermal cycler. Fluorescence endpoint reading for
allelic discrimination was performed on an ABI 7900 HT
(Applied Biosystems).
Finally, we genotyped all four AVPR2 SNPs in SMILE
controls by 5¢-nuclease/Taqman assay.
Sequencing The complete genomic region of AVPR2 was
resequenced in the DNA samples of the seven male LETS
controls who were hemizygous for the rare allele of theAVPR2
SNP S331S. A 3.3-kb region was amplified in fragments using
five sets of primers. PCR products were purified using a
QIAquick PCR Purification Kit (Qiagen Benelux, Venlo, The
Netherlands). Sequence reactions and fragment analyses
were performed by the Leiden Genome Technology
Center (www.lgtc.nl, LGTC, Leiden, The Netherlands) on
an ABI 3700 or ABI 3730 DNA Analyzer (Applied
Biosystems).
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In vitro studies
AVPR2 constructs An expression construct encoding wild-
type V2R, C-terminally tagged with green fluorescent protein
(GFP) (12G-V2R–GFP) [18], was kindly provided by A.
Oksche (FMP, Berlin, Germany). The expression construct
encoding 12E-V2R–GFP was made from 12G-V2R–GFP by
site-directed mutagenesis, using a QuikChange II Site-Directed
Mutagenesis Kit (Qiagen Benelux) and a set of 31-base
mutagenesis primers (Eurogentec). Mutagenesis was
confirmed by sequencing.
Cell culture Polarized Madin Darby Canine Kidney type II
(MDCKII) cells, which, in contrast to Madin Darby Canine
Kidney type I cells, lack endogenous V2R expression (kindly
provided byA. Oksche), were cultured at 37 C under 5%CO2
in Dulbeccos modified Eagles medium (Invitrogen, Carlsbad,
CA,USA) supplemented with 5% fetal bovine serum, 1%non-
essential amino acids, gentamicin, L-glutamine, and sodium
bicarbonate. Cells were stably transfected with 12G-V2R–GFP
or 12E-V2R–GFP constructs as described previously [19], and
colonies were selected on the basis of V2R expression.
Immunoblotting and immunocytochemistry For immuno-
blotting, cells were lysed in Laemmli buffer containing 0.1 M
dithiothreitol. High-mannose or total N-linked sugar moieties
were removed with endoglycosidase H (Endo H) or proteinN-
glycosidase F (PNGase F) (both from New England Biolabs,
Beverly, MA, USA), respectively, according to the
manufacturers protocol. Polyacrylamide gel electrophoresis,
western blotting and immunodetection were performed as
described elsewhere [19,20]. For detection of V2R–GFP, rabbit
anti-GFP serum, diluted 1 : 5000, was used (B. Wieringa,
Department of Cell Biology, RUNMC, Nijmegen, The
Netherlands). As secondary antibodies, horseradish
peroxidase-coupled goat anti-rabbit IgGs (Sigma, St Louis,
MO, USA) were used. Immunocytochemistry, confocal laser-
scanning microscopy and data quantification were performed
as described elsewhere [18]. As primary antibody, rat anti-E-
cadherin (Sigma), diluted 1 : 100, was used. As secondary
antibody, goat anti-rat IgG coupled to Alexa 594, diluted
1 : 100, was used (Molecular Probes, Leiden, The
Netherlands). Horizontal extended-focus images and vertical
images were obtained with a Bio-Rad MRC-1000 laser-
scanning confocal imaging system, using a · 60 oil-
immersion objective, a 32 Kalman collection filter, an
aperture diaphragm of 2.5, and an axial resolution of
0.14 lm per pixel. The images were contrast-stretched using
ADOBE PHOTOSHOP.
Radioligand-binding assay Untransfected MDCKII cells
and 12G-V2R–GFP-expressing or 12E-V2R–GFP-expressing
MDCKII cells were seeded at a density of 150 000 cells cm)2
on Costar filters (Corning, Corning, NY, USA) in 24-well
plates, and grown to confluence over 3–4 days. Cells were
washed twice in ice-cold phosphate-buffered saline with
0.1 mM CaCl2 and 1 mM MgCl2 (PBS-CM), and plates were
placed on ice, to prevent V2R internalization. Cells were
incubated on the basolateral side with [3H]AVP at
concentrations ranging from 0 to 100 nM in PBS-CM for 2 h
on ice. Cells were washed with PBS-CM, and filters were then
excised and added to 5 mL of Filter-Count scintillation fluid
(PerkinElmer, Waltham, MA, USA), and counted in a Tri-
Card 1600 TR Liquid Scintillation Analyzer (PerkinElmer).
Saturation curves of 12G-V2R–GFP and 12E-V2R–GFP were
baseline corrected for values counted in untransfected cells to
correct for non-specific binding. Three independent
experiments were performed in duplicate.
cAMP assay Untransfected MDCKII cells and 12G-V2R–
GFP-expressing or 12E-V2R–GFP-expressing MDCKII cells
were seeded at a density of 600 000 cells cm)2 on Costar filters
(Corning) in 24-well plates and grown to confluency overnight
in the presence of [3H]adenine (2 lCi mL)1). Cells were washed
twice with HBS buffer [25 mM HEPES, pH 7.2, supplemented
with 0.75 mM NaH2PO4, 140 mM NaCl, and 0.05% (w/v)
bovine serum albumin] and preincubated at 37 C with 1 mM
3-isobutyl-1-methylxanthine in HBS buffer. After 30 min,
25 lL of concentrated AVP solution was added
basolaterally, resulting in final AVP concentrations, on the
basolateral side of the filter, ranging from 0.0001 to 100 nM.
Cells were incubated for an additional 25 min at 37 C. Then,
cells were placed on ice, and theHBS buffer was removed. Cells
were lysed in 1 mL (0.25 mL apically and 0.75 mL
basolaterally) of 5% (w/v) trichloroacetic acid, supplemented
with 0.1 mM cAMP and 0.1 mM ATP, for at least 30 min.
Lysates were stored at ) 20 C, and cAMP was measured
within 1 week.
To measure [3H]cAMP generation, lysates were loaded onto
Dowex 50W-X4 columns (Bio-Rad, Hercules, CA, USA),
followed by 2 mL of water, with the flow-through being
discarded. Then, theDowex columns were placed over alumina
columns (Sigma) and eluted with 10 mL of water, with the
flow-through again being discarded. The alumina columns
were then placed over scintillation vials and eluted with 6 mL
of 0.1 M imidazole (Sigma). Fifteen milliliters of scintillation
fluid (Ecoscint XR; National Diagnostics, Atlanta, GA, USA)
was added to each vial, and tritium was counted for 5 min on a
Wallac 1409 Liquid Scintillation Counter. Dowex columns
were regenerated by adding 10 mL of 2 M HCl followed by
10 mL of water; the alumina columns were regenerated by
adding 2 mL of 1 M imidazole, 10 mL of 0.1 M imidazole, and
finally 5 mL of water. Three independent experiments were
performed in duplicate.
Statistical analysis
To evaluate differences in VWF propeptide, VWF and FVIII
levels between genotypes, Students t-tests and linear regression
modeling were used. Differences in mean levels, together with
95% confidence intervals (CIs) of these differences, are given.
Differences in mean levels between groups were adjusted for
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age and ABO blood group by linear regression modeling.
Because AVPR2 is located on the X-chromosome, analyses
were stratified on sex.
Data for AVP saturation experiments inMDCKII cells were
analyzed with GRAPHPAD PRISM. Maximum binding capacity
(Bmax) and dissociation constant (KD) were determined, along
with corresponding 95% CIs. The difference between KD
values was evaluated with a paired, two-tailed t-test. For
cAMP, ) log EC50 values were calculated with their corre-
sponding standard deviations, using GRAPHPAD PRISM. We
used a paired, one-tailed t-test to evaluate whether cAMP
generation was increased in 12E-V2R–GFP cells as compared
with 12G-V2R–GFP cells.
Results
Genotyping
Initially, we genotyped the LETS controls for three AVPR2
SNPs: G12E, L309L, and S331S. As described below, G12E
and S331S were associated with the levels of VWF propeptide,
VWF, and FVIII. We resequenced the entire AVPR2 genomic
region in all men who were hemizygous for these two SNPs in
the LETS, to identify variations linked toG12E and S331S.We
identified one other potentially functional polymorphism,
a-245c. Therefore, we additionally genotyped LETS and
SMILE controls for this SNP.
Genotyping was successful in all LETS controls, except for
a-245c in one individual. In the female controls, all SNPs were
in Hardy–Weinberg equilibrium. Minor allele frequencies
(MAFs) of three of the SNPs, a-245c, G12E, and S331S, were
low, namely 2.43%, 1.89%, and 2.30%, respectively, in healthy
controls. L309L was more common, and had a MAF of
25.95% in healthy controls. In the SMILE, correct genotypes
are missing in 36 controls for a-245c, in 27 for G12E, in 21 for
L309L, and in 15 for S331S, owing to sample depletion. MAFs
in controls were slightly lower than in the LETS, namely,
approximately 1.15%, 0.97% and 1.11% for a-245c, G12E,
and S331S, respectively, and 27.20% for L309L.
SNPs a-245c, G12E and S331S were strongly linked to each
other. Furthermore, rare alleles of these SNPs only occurred in
individuals also carrying rare alleles of L309L. In Table 1, we
show the AVPR2 haplotypes identified in the LETS and the
SMILE.
Associations between AVPR2 SNPs and levels of VWF
propeptide, VWF, and FVIII
Healthy LETS controls In men, associations with levels of
VWF propeptide were observed for three SNPs: a-245c, G12E,
and S331S (Table 2A). Similar associations with VWF and
FVIII were indicated. Men hemizygous for the rare alleles of
these SNPs had higher levels of VWF propeptide, VWF and
FVIII:Ag than men hemizygous for the common alleles.
FVIII:C appeared to be elevated as well, but to a lesser extent.
L309L was not associated with VWF propeptide, VWF and
FVIII levels in male controls. Associations between a-245c,
G12E and S331S and levels were not present in women
(Table 2B). However, slight increases in VWF and FVIII levels
observed in women heterozygous for these three SNPs could
suggest a gene dosage effect. Among female LETS controls,
there were no homozygous carriers of the rare alleles of a-245c,
G12E, or S331S. Adjustment for age and ABO blood group
affected outcomes in neither men nor women. In a linear
regression model, it is predicted that this cluster of SNPs
(a-245c, G12E, and S331S) can explain 2.5% of total variation
in VWF propeptide in the LETS, 1.8% of the variation in
VWF:Ag, and 2.7% of the variation in FVIII:Ag.
Healthy SMILE controls The SMILE control population
was analyzed to replicate the observations in the LETS.
Although the SMILE includes only men and lacks
measurements of VWF propetide and FVIII:Ag, we
confirmed that control subjects hemizygous for the rare
alleles of a-245c, G12E and S331S had higher levels of VWF
than those carrying the common alleles (Table 2C). The effects
on FVIII:C levels were much more moderate. In a linear
regression model, it is predicted that this cluster of SNPs
explains 3.2% of the variation in VWF:Ag and 1.3% of the
variation in FVIII:C in the SMILE. In contrast to the LETS,
an association with increased VWF and FVIII levels was also
observed for the rare allele of L309L, although the effect was
smaller than for the other SNPs. Adjustment for neither age
nor ABO blood group affected the outcomes.
In vitro studies
Transfection of MDCKII cells Of the three SNPs that are
associated with VWF propeptide, VWF and FVIII plasma
levels, G12E was the only coding, non-synonymous SNP.
Therefore, it was themost likely candidate for an effect on V2R
functioning. The potential functionality of G12E was
investigated in an in vitro model. MDCKII cells were
transfected with either 12G-V2R–GFP or 12E-V2R–GFP,
and stable cell lines were formed. Immunocytochemical
findings showed that both 12G-V2R–GFP and 12E-V2R–
GFP colocalized with the marker protein E-cadherin on the
basolateral membrane of the cells, whereas untransfected
Table 1 AVPR2 haplotypes identified in the Leiden Thrombophilia Study
and the Study of Myocardial Infarctions Leiden
Haplotype*
AVPR2
a-245c
AVPR2
G12E
AVPR2
L309L
AVPR2
S331S
1 A GGG CTA AGC
2 A GGG CTG AGC
3 C GGG CTG AGC
4 A GGG CTG AGT
5 C GGG CTG AGT
6 C GAG CTG AGT
*Haplotypes fit all but one individual; bold print indicates a nucleotide
change.
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control cells revealed no GFP signal (Fig. 1). In both
transfected cell lines, late endosomal/lysosomal localization of
V2R–GFP was observed, indicating that receptor
internalization occurred for both V2R variants (data not
shown). For AVP binding and cAMP generation experiments
(described below), GFP-positive colonies of both 12G-V2R–
GFP and 12E-V2R–GFP expressing cells with similar V2R–
GFP expression levels were selected visually.
To test whether glycosylation was normal, we treated total
cell lysates with Endo H and PNGase F to cleave off N-linked
high-mannose sugar groups (indicative of V2R localized to the
endoplasmic reticulum) or all N-linked sugar moieties, respec-
tively. GFP immunoblotting of cell lysates revealed that the
extent and form of glycosylation were similar to that of wild-
type V2R, as shown previously [20], indicating that the
processing of 12E-V2R is similar to that of 12G-V2R.
V2R binding affinity V2R saturation experiments with
[3H]AVP show similar Bmax values for both 12G-V2R and
12E-V2R cell lines, which were reached at an AVP
concentration of approximately 50–60 nM (Fig. 2A). This
indicates similar V2R expression levels in both cell lines.
However, the saturation curve of 12E-V2R is steeper than that
of 12G-V2R. The KD was 4.5 nM (95% CI 3.6–5.4) for 12E-
V2R and 16.5 nM (95% CI 10.1–22.9) for 12G-V2R,
corresponding to a three-fold increase in AVP binding
affinity for 12E-V2R as compared with 12G-V2R
(P < 0.0001).
cAMP generation To test whether increased AVP binding
affinity also leads to increased intracellular signal transduction,
we measured intracellular cAMP generation at increasing
concentrations of AVP (Fig. 2B). Both receptors were
Table 2A Mean levels of von Willebrand factor (VWF) propeptide, VWF and FVIII in healthy male controls; the Leiden Thrombophilia Study
Genotype* N
VWF propeptide
(U dL)1) VWF:Ag (IU dL)1) FVIII:Ag (IU dL)1) FVIII:C (IU dL)1)
Mean D 95% CI Mean D 95% CI Mean D CI95 N Mean D 95% CI
a-245c
A 115 114 – – 127 – – 114 – – 193 119 – –
C 5 145 31 8–53 154 28 ) 8–63 147 33 ) 3–69 6 141 22 ) 5–48
G12E
G 116 114 – – 127 – – 114 – – 195 120 – –
A 4 139 25 1–50 146 18 ) 21–58 140 26 ) 15–66 5 129 9 ) 20–38
L309L
A 97 115 – – 129 – – 116 – – 153 120 – –
G 23 115 0 ) 11–12 121 ) 9 ) 27–9 111 ) 5 ) 24–13 47 118 ) 2 ) 13–8
S331S
C 115 114 – – 127 – – 114 – – 193 119 – –
T 5 145 31 8–53 154 28 ) 8–63 147 33 ) 3–69 7 135 16 ) 9–41
CI, confidence interval; FVIII:Ag, FVIII antigen; FVIII:C, FVIII activity; VWF:Ag, VWF antigen. *As the AVPR2 gene is located on the
X-chromosome, only single alleles are shown for male study participants. Reference group. D represents the mean difference from the reference
group.
Table 2B Mean levels of von Willebrand factor (VWF) propeptide, VWF and FVIII in healthy female controls; the Leiden Thrombophilia Study
Genotype N
VWF propeptide
(U dL)1) VWF:Ag (IU dL)1) FVIII:Ag (IU dL)1) FVIII:C (IU dL)1)
Mean D 95% CI Mean D 95% CI Mean D 95% CI N Mean D 95% CI
a-245c
AA* 171 108 – – 117 – – 103 – – 258 123 – –
AC 8 101 ) 8 ) 25–9 119 3 ) 24–29 109 6 ) 22–34 12 130 7 ) 12–26
G12E
GG* 173 108 – – 117 – – 103 – – 261 123 – –
GA 6 100 ) 8 ) 28–12 127 10 ) 21 to ) 40 123 19 ) 13–52 9 138 15 ) 14–44
L309L
AA* 99 110 – – 120 – – 108 – – 146 124 – –
AG 69 106 ) 5 ) 12–3 110 ) 10 ) 21 to ) 2 95 ) 13 ) 25 to ) 1 103 119 ) 5 )13–3
GG 11 104 ) 6 ) 11–12 140 20 ) 4–45 117 9 ) 16–35 21 139 15 ) 1–30
S331S
CC* 173 109 – – 117 – – 103 – – 260 123 – –
CT 6 100 ) 8 ) 16–0 127 10 ) 21–40 123 19 ) 13–52 10 136 13 ) 8–34
CI, confidence interval; FVIII:Ag, FVIII antigen; FVIII:C, FVIII activity; VWF:Ag, VWF antigen. *Reference group. D represents the mean
difference from the reference group.
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functional, and they gave a similar maximal response for
cAMP generation at 100 nM AVP. The 12E-V2R–GFP cells
were more potent in their cAMP response at lower
concentrations of AVP. The ) log EC50 was 10.38 ± 1.35
for 12E-V2R–GFP, compared with 8.72 ± 0.56 for wild-type
12G-V2R–GFP (P = 0.05). This shows that the increased
binding affinity of 12E-V2R for AVP does indeed result in
increased intracellular signal transduction in MDCKII cells.
Untransfected MDCKII cells showed no cAMP generation in
response to AVP, even at 100 nM.
Discussion
We hypothesized that gain-of-function variations in the
AVPR2 gene would lead to increased VWF secretion from
WPBs and to increased plasma levels of VWF and FVIII. We
observed that the rare alleles of three AVPR2 SNPs, a-245c,
G12E, and S331S, were associated with increased levels of
VWF propeptide in the LETS and increased mature VWF
levels in the SMILE. The three SNPs were in strong linkage
disequilibrium, but none of the AVPR2 SNPs was linked to
three SNPs in the adjacent F8 gene [D1241E (rs1800291),
G24052A (rs6655259) andG27882C (rs28370236)], which have
previously been shown to associate with FVIII levels in the
LETS and the SMILE [21,22].
Because these three AVPR2 SNPs were in strong linkage
disequilibrium, it is likely that the observed associations were
caused by only one SNP. G12E was the most likely candidate
for functional variation, as G12E is a coding non-synonymous
SNP, located in the N-terminal extracellular tail, that may
influence ligand binding. We demonstrated a three-fold
increase in the binding affinity of 12E-V2R for AVP as
compared with wild-type 12G-V2R in stably transfected
MDCKII cells, and a corresponding increase in intracellular
cAMP generation. This means that, even though both alleles of
the SNP yield a fully functional receptor, carriers of the E-allele
will be able to respond to lower plasma concentrations of AVP.
The associations that we observed with plasma levels were
strongest forVWFpropeptide intheLETSandformatureVWF
in the SMILE inmen.AssociationswithFVIII:Ag andFVIII:C
were indicated. This suggests that VWF secretion is indeed
upregulated. Although there were no women homozygous for
G12E in theLETS, there did appear to be an intermediate effect
on VWF and FVIII levels in heterozygous women.
It should be noted, however, that the numbers of G12E
carriers are small – only five hemizygous male and nine
heterozygous female controls in the LETS, and six hemizygous
male controls in the SMILE. However, CIs around the
differences in VWF propeptide levels in men in the LETS
and VWF levels in the SMILE were narrow. Furthermore, the
fact that similar associations were observed in two independent
study populations supports the validity of these observations.
Although the effects on VWF levels in male controls were
larger in the SMILE than in the LETS, this discrepancy can, in
Table 2C Mean levels of von Willebrand factor (VWF) and FVIII
(IU mL)1) in healthy male controls; the Study of Myocardial Infarctions
Leiden
Genotype*
VWF:Ag (IU dL)1) FVIII:C (IU dL)1)
N Mean D 95% CI N Mean D 95% CI
a-245c
A 576 131 – – 602 123 – –
C 7 220 89 41–136 7 125 3 ) 22–27
G12E
G 586 131 – – 612 123 – –
A 6 242 110 60–161 6 130 7 ) 19–33
L309L
A 434 128 – – 455 122 – –
G 163 144 16 4–27 169 125 2 ) 3–8
S331S
C 596 131 – – 623 123 – –
T 7 220 89 42–136 7 125 2 ) 23–27
CI, confidence interval; FVIII:Ag, FVIII antigen; FVIII:C, FVIII
activity; VWF:Ag, VWF antigen. *As the AVPR2 gene is located on
the X-chromosome, only single alleles are shown for male study par-
ticipants. Reference group. D represents the mean difference from the
reference group.
Untransfected 12G V2R-GFP 12E V2R-GFP
Fig. 1. Arginine vasopressin 2 receptor (V2R)–green fluorescent protein (GFP) expressed in Madin Darby Canine Kidney type II (MDCKII) cells.
Localization of 12G-V2R–GFP and 12E-V2R–GFP (green) and the basolateral plasma membrane marker E-cadherin (red) in untransfected and stably
transfected MDCKII cells. Cells were visualized from above and from the side, and colocalization is visble in yellow. As primary antibody, rat anti-
E-cadherin, diluted 1 : 100, was used. As secondary antibody, goat anti-rat IgG coupled to Alexa 594, diluted 1 : 100, was used. The images were
contrast-stretched using ADOBE PHOTOSHOP. The white size bars correspond to a distance of 10 lm.
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part, be explained by a difference in age between male controls
hemizygous for G12E (59 years in the SMILE vs. 51 years in
the LETS). Finally, the in vitro data for G12E support the
associations with levels observed in both studies.
We conclude thatAVPR2 variations are modifiers of plasma
levels of VWF propeptide and VWF. The AVPR2 G12E
variant is a gain-of-function mutation that leads to normally
expressed, fully functional V2R with increased binding affinity
for AVP, and consequently with increased signal transduction
as reflected by higher intracellular cAMP generation. As 12E-
V2R can readily be activated by low levels of AVP, this
variation may lead to increased VWF secretion from WPBs,
which explains the association of G12E with higher VWF
propeptide and VWF plasma levels.
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